New stent technique could reduce deadly rebleeding in liver cirrhosis
NCT ID NCT07587671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new procedure using a special stent (underdilated VCX-TIPS) with standard treatment (endoscopic banding plus beta-blockers) to prevent variceal rebleeding in people with cirrhosis. The new approach uses a smaller balloon to expand the stent, aiming to lower pressure in the liver's blood vessels while reducing side effects like brain confusion. 240 participants who have recovered from a first variceal bleed will be randomly assigned to one of the two treatments and followed for one year to see which better prevents death or rebleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Underdilated VIATORR Controlled Expansion stent (a device placed in the liver to reduce pressure in blood vessels)
What this could lead to
If successful, this could offer a more effective way to prevent dangerous rebleeding from varices in cirrhosis patients, potentially reducing deaths and the need for repeat procedures.
What could go wrong
This is an early-stage trial with only 240 participants, so results may not apply to all patients. The underdilated stent might still cause liver problems or brain confusion (hepatic encephalopathy), and the procedure carries risks like any invasive surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
Chengdu, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
West China Xiamen Hospital, Sichuan University
Xiamen, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••